Meta-analysis of individual data from 19 double-blind trials (123,940 participants) of statin vs placebo: besides known muscle and diabetes effects, only 4 of 66 label-listed adverse outcomes were excess, eg abnormal liver transaminases 0.30% vs 0.22% per year (RR 1.41).
Meta-analysisn = 123,940
Cholesterol Treatment Trialists' (CTT) Collaboration. Electronic address: [email protected] et al. Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials